Search
Research
Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational StudyIn mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.
Research
Infant, maternal and demographic predictors of delayed vaccination: A population-based cohort studyReceiving vaccines at or close to their due date (vaccination timeliness) is a now key measure of program performance. However, studies comprehensively examining predictors of delayed infant vaccination are lacking. We aimed to identify predictors of short and longer-term delays in diphtheria-tetanus-pertussis (DTP) vaccination by dose number and ethnicity.
Research
Facilitating knowledge transfer during Australia’s COVID-19 vaccine rollout: an examination of ‘Functional Dialogues’ as an approach to bridge the evidence–policy gapOur interdisciplinary team initiated a project to inform the COVID-19 vaccination programme. We developed a novel research co-creation approach to share emerging findings with government.
Research
Optimising a 6-plex tetanus-diphtheria-pertussis fluorescent bead-based immunoassaySmall volume assays are required for large-scale research studies and in particular paediatric trials, where multiple measures are required from a single sample. Fluorescent bead-based technology (Bioplex/Luminex) allows high through-put and simultaneous quantification of multiple analytes in a single test. This technology uses sets of microspheres, each with a unique spectral address that can be coated with a different antigen of interest.
Research
Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of AgeWe assessed the impact of maternally derived pertussis antibodies on infant responses to a 2 + 1 vaccine schedule (6 weeks, 12 weeks, and 12 months). Infants with baseline antibodies showed lower IgG responses following the primary vaccination series, but this did not impair booster responses at 4 years of age.
Research
Response after one dose of monovalent influenza A (H1n1) 2009 vaccine in infants and children - preliminary reportTo assess the immunogenicity and safety of a 2009 influenza A(H1N1) vaccine in children.
Research
HPV prevalence in Canberra high school students: significance for vaccination strategies and adolescent healthHPV prevalence in Canberra high school students: significance for vaccination strategies and adolescent health.
Research
A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMRThis study evaluated GSK's combined DTPa-IPV vaccine (Infanrix-IPV) given as a fifth consecutive acellular pertussis booster dose in conjunction...
Research
Immunogenicity and boosting following a reduced number of doses of a Pneumococcal Conjugate Vaccine in infants and toddlersThe minimum number of doses of pneumococcal conjugate vaccine required for protection is not known. We studied the immunogenicity of a reduced schedule in...
Research
Trivalent influenza vaccine and febrile adverse events in australia, 2010: Clinical features and potential mechanismsIncreased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.